Stockscreener 앱 받기
10.63
4.15%
-0.46
전일 마감가:
$11.09
열려 있는:
$11.15
하루 거래량:
1.08M
Relative Volume:
0.55
시가총액:
$1.05B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-22.62
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-18.61%
1개월 성능:
-0.28%
6개월 성능:
-40.51%
1년 성능:
-12.73%
1일 변동 폭
$10.60
$11.17
1주일 범위
$10.60
$13.15
52주 변동 폭
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.63 | 1.10B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Sell Signal: Is ARS Pharmaceuticals Inc stock a falling knife or bargain buy2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Targets Report: What analysts say about ARS Pharmaceuticals Inc stock2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3%Should You Sell? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise - 富途牛牛
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Finviz
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpShould You Buy? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
What drives ARS Pharmaceuticals Inc stock priceVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
ARS Pharmaceuticals, Inc.Common Stock (NQ: SPRY - FinancialContent
ARS Pharmaceuticals, Inc. (SPRY): Investor Outlook Reveals a Compelling 162% Upside Potential - DirectorsTalk Interviews
ARS Pharma’s neffy nasal spray approved in China... - The Pharma Letter
The Technical Signals Behind (SPRY) That Institutions Follow - Stock Traders Daily
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China - Trefis
Is ARS Pharmaceuticals a buy? - Cantech Letter
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg - Yahoo Finance
China approves first community use epinephrine nasal spray for allergies By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4%Time to Buy? - MarketBeat
ARS Pharma Receives Approval For Neffy In China, Expanding Global Reach - Nasdaq
ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions - MarketScreener
China approves first community use epinephrine nasal spray for allergies - Investing.com
ARS Pharmaceuticals' neffy Approved as First Epinephrine Nasal Spray for Out-of-Hospital Use in China - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - The Manila Times
neffy® (epinephrine nasal spray) Approved in China as the - GlobeNewswire
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Trading Systems Reacting to (SPRY) Volatility - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Potential 152% Upside Captivates Investors - DirectorsTalk Interviews
With ARS Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
Is ARS Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Highlights & Reliable Volume Spike Alerts - Улправда
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 7.9% HigherWhat's Next? - MarketBeat
Can ARS Pharmaceuticals Inc. stock hit record highs againJuly 2025 Setups & Verified Trade Idea Suggestions - Bölüm Sonu Canavarı
What insider trading reveals about ARS Pharmaceuticals Inc. stockMarket Performance Report & Daily Stock Trend Watchlist - Улправда
Is ARS Pharmaceuticals Inc. stock near bottom after declineMarket Sentiment Summary & High Conviction Investment Ideas - ulpravda.ru
ARS Pharmaceuticals Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (SPRY) Movement - news.stocktradersdaily.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 6.3%Time to Buy? - MarketBeat
Is ARS Pharmaceuticals Inc a good long term investmentStock Correlation Metrics & Investment Recommendations You Can Trust - earlytimes.in
Next Century Growth Investors LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):